株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

禁煙補助薬の世界市場: 動向および予測(2017年~2022年)

Global Smoking Cessation Aids Market - Trend & Forecast (2017 - 2022)

発行 Mordor Intelligence LLP 商品コード 391363
出版日 ページ情報 英文 205 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.90円で換算しております。
Back to Top
禁煙補助薬の世界市場: 動向および予測(2017年~2022年) Global Smoking Cessation Aids Market - Trend & Forecast (2017 - 2022)
出版日: 2017年01月24日 ページ情報: 英文 205 Pages
概要

禁煙補助薬は、個人の禁煙を補助する製品で、基本的に喫煙の代替ですが、喫煙のような有害な影響はありません。 WHOによると、タバコによって毎年約600万人が死亡しています。約500万人の死亡者は、直接的なたばこ使用によるものであり、60万人以上が受動喫煙による曝露で死亡しています。世界中で10億人以上の喫煙者がいます。喫煙者の大半は、低所得国または中所得国に住んでいます。喫煙者の人口が増加し、喫煙の危険性が増していることから、禁煙補助薬市場の持続的な成長が見られます。ニコチン置換療法(NRT)は禁煙補助薬として最も好評を得ています。

当レポートでは、世界の禁煙補助薬市場を調査し、全体的な市場動向、製品・地域別の詳細動向、市場成長への影響要因の分析、競合情勢、主要企業のプロファイルなどを包括的にまとめています。

目次

第1章 イントロダクション

  • レポートについて
  • 調査方法

第2章 エグゼクティブサマリー

第3章 市場の概要

  • 市場の定義
  • 市場の成長要因
    • 大くの人々が喫煙中毒
    • 喫煙の危険性に対する意識
    • タバコ製品の広告の禁止
  • パイプライン - 現在開発中の製品
  • 市場の課題
    • 薬物の有害作用
  • ポーターのファイブフォース分析
    • サプライヤーの交渉力
    • バイヤーの交渉力
    • 競合
    • 新規参入者の脅威
    • 代替品の脅威

第4章 市場セグメンテーション

  • NRTガム
  • NRTトローチ剤
  • NRT吸入器
  • NRTパッチ
  • スプレー
  • 薬物
  • 電子たばこ
  • その他

第5章 世界市場:地域情勢

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • スペイン
  • アジア
    • インド
    • 中国
    • 日本
    • 韓国
  • その他の地域

第6章 競争的な景観

  • イントロダクション
  • M&A
  • 拡張
  • 新製品の発売
  • 協業

第7章 主要プレーヤー

  • Reckitt Benckiser Plc
  • Pfizer
  • GlaxoSmithKline Plc
  • Roche
  • Novartis
  • Johnson and Johnson
  • Bayer AG
  • Cipla Ltd.
  • 武田薬品工業
  • NJOY

第8章 付録

目次

Description

The Global market for Smoking cessation Aids Market is expected to reach $XX by the end of 2020 growing at a CAGR of around XX% from 2015 to 2021. Smoking cessation aids are products that help an individual quite smoking. It is basically an alternative to smoking but not having any hazardous effects like that of smoking. According to WHO, Tobacco kills approximately 6 million individuals every year. Around 5 million deaths are due to direct tobacco use and more than 600000 deaths are as a result of exposure to second-hand smoke. There is more than 1 billion smoking/ tobacco users' worldwide. The majority of smokers live in low- or middle income countries. Due to large population of smoking individuals and increasing awareness of hazards of smoking there is a sustained growth in the market for smoking cessation aids. Nicotine replacement therapy (NRT) have gained the largest popularity as a smoking cessation aid.

The market for smoking cessation aids have been segmented into NRT Gums, NRT Lozenges, NRT Inhalers, NRT Patches, Sprays, Drugs and electronic cigarettes. Nicotine replacement therapy has the largest market segment with many OTC products. Amongst NRT products, NRT Gums has the largest share in the market. Amongst prescription products, inhalers, and sprays have the largest market. However, there is a rapid growth in electronic cigarettes, NRT lozenges, and NRT patches market due to ease of use. The drug therapy for Smoking cessation did not have a good impact. Amongst drugs Zyban by GSK and Chantix by Pfizer are used as first line therapy. However, due to many adverse effects of these drugs like suicidal tendency etc., there have been a decline in market of drug as a smoking cessation aid. The key players in smoking cessation therapy market are GlaxoSmithKline, Pfizer, Novartis, Johnson and Johnson, Cipla Ltd. And others.

Drivers

Large Tobacco Consuming Population, Awareness amongst Smokers on hazards of smoking, Banning of Tobacco product advertisement in many countries are the key factors augmenting the market as market driver.

Challenges

Adverse effect of drugs, is one the challenge that drug therapy market for Smoking cessation has witnessed.

What the report offers:

1) Market Definition for the specified topic along with identification of key drivers and restraints for the market.

2) Market analysis for the Smoking cessation Aids Market, with region specific assessments and competition analysis on a global and regional scale.

3) Identification of factors instrumental in changing the market scenarios, rising prospective opportunities and identification of key companies which can influence the market on a global and regional scale.

4) Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market shares

5) Identification and analysis of the Macro and Micro factors that affect the Smoking cessation Aids Market on both global and regional scale.

6) A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.

Table of Contents

1. Introduction

  • 1.1 Report Desciption
  • 1.2 Research Methodology

2. Executive Summary

3. Market Overview

  • 3.1 Market Definition
  • 3.2 Market Drivers
    • 3.2.1 Large Population Addicted to smoking
    • 3.2.2 Awareness on hazards of Smoking
    • 3.2.3 Banning Advertisements of Tobacco products
  • 3.3 Pipeline - Products currently in development
  • 3.4 Market Challenges
    • 3.4.1 Adverse effects of Drugs
  • 3.5 Porter's five forces for cord blood stem cell market
    • 3.5.1 Bargaining power of suppliers
    • 3.5.2 Bargaining power of buyers
    • 3.5.3 Competition
    • 3.5.4 Threats of new entrants
    • 3.5.5 Threats from substitutes

4. Market Segmentation

  • 4.1 NRT Gum
  • 4.2 NRT lozenges
  • 4.3 NRT Inhalers
  • 4.4 NRT Patches
  • 4.5 Sprays
  • 4.5 Drugs
  • 4.7 Electronic Ciggarettes
  • 4.8 Others

5. Global Market: Geographical Landscape

  • 5.1 North America
    • 5.1.1 USA
    • 5.1.2 Canada
    • 5.1.3 Mexico
  • 5.2 Europe
    • 5.2.1 UK
    • 5.2.2 Germany
    • 5.2.3 France
    • 5.2.3 Spain
  • 5.3 Asia
    • 5.3.1 India
    • 5.3.2 China
    • 5.3.3 Japan
    • 5.3.4 South Korea
  • 5.4 Rest of the World

6. Competitive landscape

  • 6.1 Introduction
  • 6.2 Mergers and Acquisition
  • 6.3 Expansion
  • 6.4 New Product Launch
  • 6.5 Colllaborations

7. Key Players

  • 7.1 Reckitt Benckiser Plc
  • 7.2 Pfizer
  • 7.3 GlaxoSmithKline Plc
  • 7.4 Roche
  • 7.5 Novartis
  • 7.6 Johnson and Johnson
  • 7.7 Bayer AG
  • 7.8 Cipla Ltd.
  • 7.9 Takeda Pharmaceuticals Co. Ltd.
  • 7.10 NJOY

8. Appendix

Back to Top